1	Activation-dependent	activation-dependent	_	_	_	_	_	_	_
2	transcriptional	transcriptional	_	_	_	_	_	_	_
3	regulation	regulation	_	_	_	_	_	_	_
4	of	of	_	_	_	_	_	_	_
5	the	the	_	_	_	_	_	_	_
6	human	human	_	_	_	_	_	_	_
7	Fas	Fas	_	_	_	_	_	_	_
8	promoter	promoter	_	_	_	_	_	_	_
9	requires	require	_	_	_	_	_	_	_
10	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
11	p50-p65	p50-p65	_	_	_	_	_	_	_
12	recruitment	recruitment	_	_	_	_	_	_	_
13	.	.	_	_	_	_	_	_	_

1	Fas	Fas	_	_	_	_	_	_	_
2	(	(	_	_	_	_	_	_	_
3	CD95	CD95	_	_	_	_	_	_	_
4	)	)	_	_	_	_	_	_	_
5	and	and	_	_	_	_	_	_	_
6	Fas	Fas	_	_	_	_	_	_	_
7	ligand	ligand	_	_	_	_	_	_	_
8	(	(	_	_	_	_	_	_	_
9	CD95L	CD95L	_	_	_	_	_	_	_
10	)	)	_	_	_	_	_	_	_
11	are	be	_	_	_	_	_	_	_
12	an	an	_	_	_	_	_	_	_
13	interacting	interact	_	_	_	_	_	_	_
14	receptor-ligand	receptor-ligand	_	_	_	_	_	_	_
15	pair	pair	_	_	_	_	_	_	_
16	required	require	_	_	_	_	_	_	_
17	for	for	_	_	_	_	_	_	_
18	immune	immune	_	_	_	_	_	_	_
19	homeostasis	homeostasis	_	_	_	_	_	_	_
20	.	.	_	_	_	_	_	_	_

1	Lymphocyte	Lymphocyte	_	_	_	_	_	_	_
2	activation	activation	_	_	_	_	_	_	_
3	results	result	_	_	_	_	_	_	_
4	in	in	_	_	_	_	_	_	_
5	the	the	_	_	_	_	_	_	_
6	upregulation	upregulation	_	_	_	_	_	_	_
7	of	of	_	_	_	_	_	_	_
8	Fas	Fas	_	_	_	_	_	_	_
9	expression	expression	_	_	_	_	_	_	_
10	and	and	_	_	_	_	_	_	_
11	the	the	_	_	_	_	_	_	_
12	acquisition	acquisition	_	_	_	_	_	_	_
13	of	of	_	_	_	_	_	_	_
14	sensitivity	sensitivity	_	_	_	_	_	_	_
15	to	to	_	_	_	_	_	_	_
16	FasL-mediated	fasl-mediated	_	_	_	_	_	_	_
17	apoptosis	apoptosis	_	_	_	_	_	_	_
18	.	.	_	_	_	_	_	_	_

1	Although	although	_	_	_	_	_	_	_
2	Fas	Fas	_	_	_	_	_	_	_
3	upregulation	upregulation	_	_	_	_	_	_	_
4	is	be	_	_	_	_	_	_	_
5	central	central	_	_	_	_	_	_	_
6	to	to	_	_	_	_	_	_	_
7	the	the	_	_	_	_	_	_	_
8	preservation	preservation	_	_	_	_	_	_	_
9	of	of	_	_	_	_	_	_	_
10	immunologic	immunologic	_	_	_	_	_	_	_
11	tolerance	tolerance	_	_	_	_	_	_	_
12	,	,	_	_	_	_	_	_	_
13	little	little	_	_	_	_	_	_	_
14	is	be	_	_	_	_	_	_	_
15	known	know	_	_	_	_	_	_	_
16	about	about	_	_	_	_	_	_	_
17	the	the	_	_	_	_	_	_	_
18	molecular	molecular	_	_	_	_	_	_	_
19	machinery	machinery	_	_	_	_	_	_	_
20	underlying	underlie	_	_	_	_	_	_	_
21	this	this	_	_	_	_	_	_	_
22	process	process	_	_	_	_	_	_	_
23	.	.	_	_	_	_	_	_	_

1	To	to	_	_	_	_	_	_	_
2	investigate	investigate	_	_	_	_	_	_	_
3	the	the	_	_	_	_	_	_	_
4	events	event	_	_	_	_	_	_	_
5	involved	involve	_	_	_	_	_	_	_
6	in	in	_	_	_	_	_	_	_
7	activation-induced	activation-induced	_	_	_	_	_	_	_
8	Fas	Fas	_	_	_	_	_	_	_
9	upregulation	upregulation	_	_	_	_	_	_	_
10	,	,	_	_	_	_	_	_	_
11	we	we	_	_	_	_	_	_	_
12	have	have	_	_	_	_	_	_	_
13	examined	examine	_	_	_	_	_	_	_
14	mRNA	mrna	_	_	_	_	_	_	_
15	accumulation	accumulation	_	_	_	_	_	_	_
16	,	,	_	_	_	_	_	_	_
17	fas	fas	_	_	_	_	_	_	_
18	promoter	promoter	_	_	_	_	_	_	_
19	activity	activity	_	_	_	_	_	_	_
20	,	,	_	_	_	_	_	_	_
21	and	and	_	_	_	_	_	_	_
22	protein	protein	_	_	_	_	_	_	_
23	expression	expression	_	_	_	_	_	_	_
24	in	in	_	_	_	_	_	_	_
25	the	the	_	_	_	_	_	_	_
26	Jurkat	Jurkat	_	_	_	_	_	_	_
27	T-cell	T-cell	_	_	_	_	_	_	_
28	line	line	_	_	_	_	_	_	_
29	treated	treat	_	_	_	_	_	_	_
30	with	with	_	_	_	_	_	_	_
31	phorbol	phorbol	_	_	_	_	_	_	_
32	myristate	myristate	_	_	_	_	_	_	_
33	acetate	acetate	_	_	_	_	_	_	_
34	and	and	_	_	_	_	_	_	_
35	ionomycin	ionomycin	_	_	_	_	_	_	_
36	(	(	_	_	_	_	_	_	_
37	P/I	P/I	_	_	_	_	_	_	_
38	)	)	_	_	_	_	_	_	_
39	,	,	_	_	_	_	_	_	_
40	pharmacological	pharmacological	_	_	_	_	_	_	_
41	mimics	mimic	_	_	_	_	_	_	_
42	of	of	_	_	_	_	_	_	_
43	T-cell	t-cell	_	_	_	_	_	_	_
44	receptor	receptor	_	_	_	_	_	_	_
45	activation	activation	_	_	_	_	_	_	_
46	.	.	_	_	_	_	_	_	_

1	Although	although	_	_	_	_	_	_	_
2	resting	rest	_	_	_	_	_	_	_
3	Jurkat	Jurkat	_	_	_	_	_	_	_
4	cells	cell	_	_	_	_	_	_	_
5	express	express	_	_	_	_	_	_	_
6	Fas	Fas	_	_	_	_	_	_	_
7	,	,	_	_	_	_	_	_	_
8	Fas	Fas	_	_	_	_	_	_	_
9	mRNA	mRNA	_	_	_	_	_	_	_
10	was	be	_	_	_	_	_	_	_
11	induced	induce	_	_	_	_	_	_	_
12	approximately	approximately	_	_	_	_	_	_	_
13	10-fold	10-fold	_	_	_	_	_	_	_
14	in	in	_	_	_	_	_	_	_
15	2	2	_	_	_	_	_	_	_
16	h	h	_	_	_	_	_	_	_
17	upon	upon	_	_	_	_	_	_	_
18	P/I	P/I	_	_	_	_	_	_	_
19	stimulation	stimulation	_	_	_	_	_	_	_
20	.	.	_	_	_	_	_	_	_

1	Using	use	_	_	_	_	_	_	_
2	sequential	sequential	_	_	_	_	_	_	_
3	deletion	deletion	_	_	_	_	_	_	_
4	mutants	mutant	_	_	_	_	_	_	_
5	of	of	_	_	_	_	_	_	_
6	the	the	_	_	_	_	_	_	_
7	human	human	_	_	_	_	_	_	_
8	fas	fas	_	_	_	_	_	_	_
9	promoter	promoter	_	_	_	_	_	_	_
10	in	in	_	_	_	_	_	_	_
11	transient	transient	_	_	_	_	_	_	_
12	transfection	transfection	_	_	_	_	_	_	_
13	assays	assay	_	_	_	_	_	_	_
14	,	,	_	_	_	_	_	_	_
15	we	we	_	_	_	_	_	_	_
16	identified	identify	_	_	_	_	_	_	_
17	a	a	_	_	_	_	_	_	_
18	47-bp	47-bp	_	_	_	_	_	_	_
19	sequence	sequence	_	_	_	_	_	_	_
20	(	(	_	_	_	_	_	_	_
21	positions	position	_	_	_	_	_	_	_
22	-306	-306	_	_	_	_	_	_	_
23	to	to	_	_	_	_	_	_	_
24	-260	-260	_	_	_	_	_	_	_
25	relative	relative	_	_	_	_	_	_	_
26	to	to	_	_	_	_	_	_	_
27	the	the	_	_	_	_	_	_	_
28	ATG	ATG	_	_	_	_	_	_	_
29	)	)	_	_	_	_	_	_	_
30	required	require	_	_	_	_	_	_	_
31	for	for	_	_	_	_	_	_	_
32	activation-driven	activation-driven	_	_	_	_	_	_	_
33	fas	fas	_	_	_	_	_	_	_
34	upregulation	upregulation	_	_	_	_	_	_	_
35	.	.	_	_	_	_	_	_	_

1	Sequence	sequence	_	_	_	_	_	_	_
2	analysis	analysis	_	_	_	_	_	_	_
3	revealed	reveal	_	_	_	_	_	_	_
4	the	the	_	_	_	_	_	_	_
5	presence	presence	_	_	_	_	_	_	_
6	of	of	_	_	_	_	_	_	_
7	a	a	_	_	_	_	_	_	_
8	previously	previously	_	_	_	_	_	_	_
9	unrecognized	unrecognized	_	_	_	_	_	_	_
10	composite	composite	_	_	_	_	_	_	_
11	binding	binding	_	_	_	_	_	_	_
12	site	site	_	_	_	_	_	_	_
13	for	for	_	_	_	_	_	_	_
14	both	both	_	_	_	_	_	_	_
15	the	the	_	_	_	_	_	_	_
16	Sp1	sp1	_	_	_	_	_	_	_
17	and	and	_	_	_	_	_	_	_
18	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
19	transcription	transcription	_	_	_	_	_	_	_
20	factors	factor	_	_	_	_	_	_	_
21	at	at	_	_	_	_	_	_	_
22	positions	position	_	_	_	_	_	_	_
23	-295	-295	_	_	_	_	_	_	_
24	to	to	_	_	_	_	_	_	_
25	-286	-286	_	_	_	_	_	_	_
26	.	.	_	_	_	_	_	_	_

1	Electrophoretic	electrophoretic	_	_	_	_	_	_	_
2	mobility	mobility	_	_	_	_	_	_	_
3	shift	shift	_	_	_	_	_	_	_
4	assay	assay	_	_	_	_	_	_	_
5	(	(	_	_	_	_	_	_	_
6	EMSA	EMSA	_	_	_	_	_	_	_
7	)	)	_	_	_	_	_	_	_
8	and	and	_	_	_	_	_	_	_
9	supershift	supershift	_	_	_	_	_	_	_
10	analyses	analysis	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	this	this	_	_	_	_	_	_	_
13	region	region	_	_	_	_	_	_	_
14	documented	document	_	_	_	_	_	_	_
15	constitutive	constitutive	_	_	_	_	_	_	_
16	binding	binding	_	_	_	_	_	_	_
17	of	of	_	_	_	_	_	_	_
18	Sp1	sp1	_	_	_	_	_	_	_
19	in	in	_	_	_	_	_	_	_
20	unactivated	unactivated	_	_	_	_	_	_	_
21	nuclear	nuclear	_	_	_	_	_	_	_
22	extracts	extract	_	_	_	_	_	_	_
23	and	and	_	_	_	_	_	_	_
24	inducible	inducible	_	_	_	_	_	_	_
25	binding	binding	_	_	_	_	_	_	_
26	of	of	_	_	_	_	_	_	_
27	p50-p65	p50-p65	_	_	_	_	_	_	_
28	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
29	heterodimers	heterodimer	_	_	_	_	_	_	_
30	after	after	_	_	_	_	_	_	_
31	P/I	P/I	_	_	_	_	_	_	_
32	activation	activation	_	_	_	_	_	_	_
33	.	.	_	_	_	_	_	_	_

1	Sp1	Sp1	_	_	_	_	_	_	_
2	and	and	_	_	_	_	_	_	_
3	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
4	transcription	transcription	_	_	_	_	_	_	_
5	factor	factor	_	_	_	_	_	_	_
6	binding	binding	_	_	_	_	_	_	_
7	was	be	_	_	_	_	_	_	_
8	shown	show	_	_	_	_	_	_	_
9	to	to	_	_	_	_	_	_	_
10	be	be	_	_	_	_	_	_	_
11	mutually	mutually	_	_	_	_	_	_	_
12	exclusive	exclusive	_	_	_	_	_	_	_
13	by	by	_	_	_	_	_	_	_
14	EMSA	EMSA	_	_	_	_	_	_	_
15	displacement	displacement	_	_	_	_	_	_	_
16	studies	study	_	_	_	_	_	_	_
17	with	with	_	_	_	_	_	_	_
18	purified	purify	_	_	_	_	_	_	_
19	recombinant	recombinant	_	_	_	_	_	_	_
20	Sp1	sp1	_	_	_	_	_	_	_
21	and	and	_	_	_	_	_	_	_
22	recombinant	recombinant	_	_	_	_	_	_	_
23	p50	p50	_	_	_	_	_	_	_
24	.	.	_	_	_	_	_	_	_

1	The	the	_	_	_	_	_	_	_
2	functional	functional	_	_	_	_	_	_	_
3	contribution	contribution	_	_	_	_	_	_	_
4	of	of	_	_	_	_	_	_	_
5	the	the	_	_	_	_	_	_	_
6	kappaB-Sp1	kappab-sp1	_	_	_	_	_	_	_
7	composite	composite	_	_	_	_	_	_	_
8	site	site	_	_	_	_	_	_	_
9	in	in	_	_	_	_	_	_	_
10	P/I-inducible	p/i-inducible	_	_	_	_	_	_	_
11	fas	fas	_	_	_	_	_	_	_
12	promoter	promoter	_	_	_	_	_	_	_
13	activation	activation	_	_	_	_	_	_	_
14	was	be	_	_	_	_	_	_	_
15	verified	verify	_	_	_	_	_	_	_
16	by	by	_	_	_	_	_	_	_
17	using	use	_	_	_	_	_	_	_
18	kappaB-Sp1	kappab-sp1	_	_	_	_	_	_	_
19	concatamers	concatamer	_	_	_	_	_	_	_
20	(	(	_	_	_	_	_	_	_
21	-295	-295	_	_	_	_	_	_	_
22	to	to	_	_	_	_	_	_	_
23	-286	-286	_	_	_	_	_	_	_
24	)	)	_	_	_	_	_	_	_
25	in	in	_	_	_	_	_	_	_
26	a	a	_	_	_	_	_	_	_
27	thymidine	thymidine	_	_	_	_	_	_	_
28	kinase	kinase	_	_	_	_	_	_	_
29	promoter-driven	promoter-driven	_	_	_	_	_	_	_
30	reporter	reporter	_	_	_	_	_	_	_
31	construct	construct	_	_	_	_	_	_	_
32	and	and	_	_	_	_	_	_	_
33	native	native	_	_	_	_	_	_	_
34	promoter	promoter	_	_	_	_	_	_	_
35	constructs	construct	_	_	_	_	_	_	_
36	in	in	_	_	_	_	_	_	_
37	Jurkat	Jurkat	_	_	_	_	_	_	_
38	cells	cell	_	_	_	_	_	_	_
39	overexpressing	overexpresse	_	_	_	_	_	_	_
40	IkappaB-alpha	IkappaB-alpha	_	_	_	_	_	_	_
41	.	.	_	_	_	_	_	_	_

1	Site-directed	site-directed	_	_	_	_	_	_	_
2	mutagenesis	mutagenesis	_	_	_	_	_	_	_
3	of	of	_	_	_	_	_	_	_
4	the	the	_	_	_	_	_	_	_
5	critical	critical	_	_	_	_	_	_	_
6	guanine	guanine	_	_	_	_	_	_	_
7	nucleotides	nucleotide	_	_	_	_	_	_	_
8	in	in	_	_	_	_	_	_	_
9	the	the	_	_	_	_	_	_	_
10	kappaB-Sp1	kappab-sp1	_	_	_	_	_	_	_
11	element	element	_	_	_	_	_	_	_
12	documented	document	_	_	_	_	_	_	_
13	the	the	_	_	_	_	_	_	_
14	essential	essential	_	_	_	_	_	_	_
15	role	role	_	_	_	_	_	_	_
16	of	of	_	_	_	_	_	_	_
17	this	this	_	_	_	_	_	_	_
18	site	site	_	_	_	_	_	_	_
19	in	in	_	_	_	_	_	_	_
20	activation-dependent	activation-dependent	_	_	_	_	_	_	_
21	fas	fas	_	_	_	_	_	_	_
22	promoter	promoter	_	_	_	_	_	_	_
23	induction	induction	_	_	_	_	_	_	_
24	.	.	_	_	_	_	_	_	_

